logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Editas Medicine: Business Highlights and Financial Results Reported

Editas Medicine Reporting Editas Medicine ( EDIT ) reported business highlights and financial results for the first quarter of 2021. The reporting started with James C. Mullen, Chairman, President and Chief Executive Officer, Editas Medicine stating that Editas’ team is...

Read More

May 5, 2021

0

Why IVERIC bio Rallied Today

IVERIC bio's Rally IVERIC Bio ( ISEE ) announced that the U.S. ( FDA ) has granted Breakthrough Therapy designation for avacincaptad pegol ( ACP ), also known as Zimura®. Zimura is a novel investigational complement C5 inhibitor aimed at treating...

Read More

November 18, 2022

0

Madrigal Pharmaceuticals and Akero Therapeutics: After Having No Treatment for NASH, We Now Have Two Products Expected to be Approved

Treatments for NASH Madrigal Pharmaceuticals ( MDGL ) is the second company after Akero Therapeutics ( AKRO ) to announce positive top-line late results for Nonalcoholic steatohepatitis (NASH). Its product resmetirom - a liver-directed selective thyroid hormone receptor agonist has...

Read More

December 19, 2022

0

AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in Netherlands to Start Phase 1b/2 Study Evaluating Ampligen in Combination with AstraZeneca Imfinzi for Treatment of Pancreatic Cancer

AIM ImmunoTech Announcement AIM ImmunoTech ( AIM ) - an immuno-pharma company focused on the research and development of its TLR-3 agonist Ampligen (rintatolimod) as a novel and potentially powerful therapeutic in locally advanced pancreatic cancer ( “LAPC” ) and...

Read More

June 27, 2023

0

Why Kala Pharmaceuticals Stock is Soaring

Kala Pharmaceuticals  Kala Pharmaceuticals ( KALA )  announced today that the U.S. FDA has accepted the investigational new drug application ( IND ) for its lead product candidate, KPI-012, a human Mesenchymal Stem Cell Secretome ( MSC-S ) for the...

Read More

December 28, 2022

0

Compugen: First Quarter Financial Results, Accomplishments and Future Plans

Compugen Updated Trial Data  Updated data from COM701 Phase 1 combination and monotherapy studies to be presented at the American Society of Clinical Oncology ( ASCO ) 2021 Annual Meeting Milestone rich 2021 to include data readouts from ongoing COM701...

Read More

May 13, 2021

0

An Important Agreement Between Bristol-Myers Squibb and Agenus

Bristol-Myers Squibb and Agenus Agreement for AGEN1777 Bristol-Myers Squibb ( BMY ) and Agenus ( AGEN ) today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to...

Read More

May 18, 2021

0

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

CytomX and Moderna in the NEWS On January 05, 2023,  CytomX Therapeutics ( CTMX ) and Moderna Inc ( MRNA )  announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna’s mRNA technologies and CytomX’s Probody therapeutic...

Read More

January 5, 2023

0

Annovis Bio Inc: Very Encouraging Trial Results in Neurodegenerative Diseases

Annovis Bio Inc and Neurodegenerative Diseases Annovis Bio Inc ( ANVS ) , a clinical-stage drug platform company. This firm's focus is the treatment of neurodegenerative diseases. Annovis Bio Inc announced today new results from a double-blind, placebo-controlled study of...

Read More

May 21, 2021

0

Shoreline Biosciences to Acquire Editas Medicine’s iNK cell franchise

Shoreline Biosciences to Acquire Editas Medicine’s iNK cell franchise Editas Medicine, Inc. ( EDIT ) , announced that it has entered into a definitive agreement with the private Shoreline Biosciences (Shoreline) to license Editas Medicine’s proprietary SLEEK (SeLection by Essential-gene Exon...

Read More

January 19, 2023

0

  • Previous
  • 1
  • 2
  • ...
  • 138
  • 139
  • 140
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy